Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2286-2295

  Colland, Frédéric ^a   Formstecher, Etienne ^a   Jacq, Xavier ^a   Reverdy, Céline ^a   Planquette, Cécile ^a   Conrath, Susan ^a   Trouplin, Virginie ^a   Bianchi, Julie ^a   Aushev, Vasily N ^b   Camonis, Jacques ^b   Calabrese, Alessandra ^a   Borg Capra, Catherine ^a   Sippl, Wolfgang ^c   Collura, Vincent ^a   Boissy, Guillaume ^a   Rain, Jean Christophe ^a   Guedat, Philippe ^a   Delansorne, Rémi ^a   Daviet, Laurent ^a  

^a Hybrigenics SA   (France)

^b INSTITUT CURIE   (France)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CALPAIN 1; CASPASE 3; CATHEPSIN B; CATHEPSIN D; CATHEPSIN E; CATHEPSIN L; CATHEPSIN S; DIPEPTIDYL CARBOXYPEPTIDASE; HBX 41108; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMIN; PROTEASOME; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEINASE; PROTEINASE INHIBITOR; RENIN; THROMBIN; TRYPSIN; UBIQUITIN; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SPECIFICITY; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN STABILITY; PROTEINASE INHIBITION; RNA INTERFERENCE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDENES; PROTEASE INHIBITORS; PYRAZINES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE;

EID: 68849126660     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0097     Document Type: Article

References (35)

1. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006;6:776-88.
2. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006;443:780-6.
3. Gao G, Luo H. The ubiquitin-proteasome pathway in viral infections. Can J Physiol Pharmacol 2006;84:5-14.
4. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
5. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
6. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005;123:773-86.
7. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008;90:270-83.
8. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J 1997;16:1519-30.
9. Holowaty MN, Zeghouf M, Wu H, et al. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 2003;278:29987-94.
10. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004;428. 1 p following 486.
11. Cummins JM, Vogelstein B. HAUSP is required for p53 destabilization. Cell Cycle 2004;3:689-92.
12. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-2 pathway. Mol Cell 2004;13:879-86.
13. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-53.
14. Hu M, Gu L, Li M, Jeffrey PD, Gu W, Shi Y. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol 2006;4:e27.
15. Colland F. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic - AACR Special Conference. IDrugs 2006;9:179-81.
16. Becker K, Marchenko ND, Palacios G, Moll UM. A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle 2008;7:1205-13.
17. van der Horst A, de Vries-Smits AM, Brenkman AB, et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 2006;8:1064-73.
18. Song MS, Salmena L, Carracedo A, et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008;455:813-7.
19. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 2007;26:923-34.
20. Meulmeester E, Maurice MM, Boutell C, et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 2005;18:565-76.
21. Dang LC, Melandri FD, Stein RL. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 1998;37:1868-79.
22. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
23. Monge A, Arrault A, Marot C, Morin-Allory L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol Divers 2006;10:389-403.
24. Liu Y, Lashuel HA, Choi S, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003;10:837-46.
25. Hu M, Li P, Li M, et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 2002;111:1041-54.
26. Berman HM, Westbrook J, Feng Z. The Protein Data Bank. Nucleic Acids Res 2000;28:235-42.
27. Wang R, Lu Y, Wang S. Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 2003;46:2287-303.
28. Moreau P, Gaillard N, Marminon C, et al. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Bioorg Med Chem 2003;11:4871-9.
29. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
30. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
31. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006;107:4109-14.
32. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005;7:547-59.
33. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34.
34. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006;10:501-14.
35. van der Knaap JA, Kumar BR, Moshkin YM, et al. GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Mol Cell 2005;17:695-707.